Celltrion to Supply Antibody Treatment for COVID-19 Without Profit Margin in S. Korea
SEOUL, Feb. 20 (Korea Bizwire) — South Korean biopharmaceutical company Celltrion Inc. will supply its antibody treatment for COVID-19 without a profit margin in South Korea, its chairman has said. Celltrion’s CT-P59 won the South Korean drug safety agency’s conditional approval earlier this month, becoming the first locally made treatment for the virus. The drug [...]